Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keeton

Showing results (541-550 of 547) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 547 results.
Cancer Research|December 19, 2024
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerJeremy B Foote, Tyler E Mattox, Adam B Keeton, et al.
Science Advances|June 5, 2021
Natural climate solutions for CanadaC Ronnie Drever, Susan C Cook-Patton, Fardausi Akhter, et al.
Nature|February 1, 2022
T cell responses to SARS-CoV-2 spike cross-recognize OmicronRoanne Keeton, Marius B Tincho, Amkele Ngomti, et al.
PLOS Global Public Health|December 5, 2024
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA studyNigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
PLOS Global Public Health|April 11, 2024
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
Neuro-Oncology Advances|July 21, 2023
Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testingKristyn Galbraith, Varshini Vasudevaraja, Jonathan Serrano, et al.
Pageof 55

Showing results (541-550 of 547) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 547 results.
Cancer Research|December 19, 2024
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerJeremy B Foote, Tyler E Mattox, Adam B Keeton, et al.
Science Advances|June 5, 2021
Natural climate solutions for CanadaC Ronnie Drever, Susan C Cook-Patton, Fardausi Akhter, et al.
Nature|February 1, 2022
T cell responses to SARS-CoV-2 spike cross-recognize OmicronRoanne Keeton, Marius B Tincho, Amkele Ngomti, et al.
PLOS Global Public Health|December 5, 2024
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA studyNigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, et al.
Medrxiv : the Preprint Server for Health Sciences|December 4, 2023
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
PLOS Global Public Health|April 11, 2024
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Jinal N Bhiman, Yashica Ganga, et al.
Neuro-Oncology Advances|July 21, 2023
Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testingKristyn Galbraith, Varshini Vasudevaraja, Jonathan Serrano, et al.
Pageof 55